二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病的临床疗效及安全性评价(1)
[摘要] 目的 研究二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病的临床应用疗效及安全性。 方法 纳入2016年2月～2018年2月科室收治的2型糖尿病患者138例，随机分为两组：对照组69例，接受二甲双胍联合地特胰岛素治疗;试验组69例，接受二甲双胍联合利拉鲁肽治疗，比较两组的治疗效果、不良反应发生率、体重、血糖等指标。 结果 试验组的总有效率95.65%，高于对照组的78.26%，差异有统计学意义(P<0.05);试验组不良反应发生率与对照组比较，差异无统计学意义(P>0.05);试验组腰围、体重指数等指标均低于对照组，差异显著(P<0.05);试验组FBG、2hPG、HbA1c、HOMA-IR等指标低于对照组，差异有统计学意义(P<0.05)。 结论 肥胖2型糖尿病患者接受二甲双胍联合利拉鲁肽治疗3个月后，能够有效降低患者的血糖水平，安全性高，值得推广应用。
[关键词] 2型糖尿病;二甲双胍;利拉鲁肽;不良反应
[中图分类号] R000 [文献标识码] B [文章编号] 1673-9701(2019)17-0098-04
[Abstract] Objective To study the clinical efficacy and safety of metformin combined with liraglutide in the treatment of obese type 2 diabetes. Methods A total of 138 patients with type 2 diabetes admitted in the department from February 2016 to February 2018 in 2016 were randomly divided into two groups. 69 patients in the control group were treated with metformin combined with insulin detemir. 69 patients in the experimental group received metformin combined with larupeptide treatment. The treatment effect， adverse reaction rate， body weight， blood sugar and other indicators between two groups were compared. Results The total effective rate of the experimental group was 95.65%， which was higher than that of the control group(78.26%). The difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was not significantly different from that of the control group(P>0.05). The waist circumference and body mass index of the experimental group were lower than the control group， and the difference was significant(P<0.05). The FBG， 2hPG， HbA1c， HOMA-IR and other indicators in the experimental group were lower than those of the control group， and the difference was statistically significant(P<0.05). Conclusion Obese patients with type 2 diabetes can effectively reduce the blood glucose level of patients after receiving metformin and liraglutide for 3 months. It has high safety and is worthy of popularization and application.
[Key words] Type 2 diabetes;Metformin;Liraglutide;Adverse reactions
糖尿病在中國有较高的发病率和致残率[1]。肥胖尤其腹型肥胖在2型糖尿病的发生发展中起重要作用，能增加胰岛素抵抗，是糖尿病心血管并发症的危险因素之一[2]。传统口服降糖药及胰岛素，在降糖的同时常伴体重增加及低血糖发作[3]，是临床上较难解决的问题之一。利拉鲁肽作为一种胰高血糖素样肽-1(GLP-1)类似物，在降糖的同时有可减轻体重。本文主要研究二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病的临床应用疗效及安全性，现报道如下。
1 对象与方法
1.1 研究对象
纳入2016年2月～2018年2月在我院门诊和病房就诊的2型糖尿病患者138例，随机分为对照组和试验组。对照组69例，男38例，女31例，平均年龄(64.36±6.17)岁，平均病程(8.93±0.84)年。试验组69例，男39例，女30例，平均年龄(65.53±6.20)岁，平均病程(9.42±0.91)年。所有患者均符合1999年WHO定义的2型糖尿病诊断标准。纳入标准;入选前所有患者均口服降糖药治疗;无胰岛素治疗史;体重指数>25 kg/m2;糖化血红蛋白(HbA1c)>8.5%[4]。排除标准：肝肾功能不全者;恶性肿瘤者;妊娠、哺乳期女性;急性感染或应激者;慢性甲状腺疾病者;精神疾病和功能障碍者;慢性胰腺炎患者;严重心脑血管疾病者[5]。两组患者基本资料比较，差异无统计学意义(P>0.05)。, 百拇医药(仇海燕 孔利萍 马丽珍)
[关键词] 2型糖尿病;二甲双胍;利拉鲁肽;不良反应
[中图分类号] R000 [文献标识码] B [文章编号] 1673-9701(2019)17-0098-04
[Abstract] Objective To study the clinical efficacy and safety of metformin combined with liraglutide in the treatment of obese type 2 diabetes. Methods A total of 138 patients with type 2 diabetes admitted in the department from February 2016 to February 2018 in 2016 were randomly divided into two groups. 69 patients in the control group were treated with metformin combined with insulin detemir. 69 patients in the experimental group received metformin combined with larupeptide treatment. The treatment effect， adverse reaction rate， body weight， blood sugar and other indicators between two groups were compared. Results The total effective rate of the experimental group was 95.65%， which was higher than that of the control group(78.26%). The difference was statistically significant(P<0.05). The incidence of adverse reactions in the experimental group was not significantly different from that of the control group(P>0.05). The waist circumference and body mass index of the experimental group were lower than the control group， and the difference was significant(P<0.05). The FBG， 2hPG， HbA1c， HOMA-IR and other indicators in the experimental group were lower than those of the control group， and the difference was statistically significant(P<0.05). Conclusion Obese patients with type 2 diabetes can effectively reduce the blood glucose level of patients after receiving metformin and liraglutide for 3 months. It has high safety and is worthy of popularization and application.
[Key words] Type 2 diabetes;Metformin;Liraglutide;Adverse reactions
糖尿病在中國有较高的发病率和致残率[1]。肥胖尤其腹型肥胖在2型糖尿病的发生发展中起重要作用，能增加胰岛素抵抗，是糖尿病心血管并发症的危险因素之一[2]。传统口服降糖药及胰岛素，在降糖的同时常伴体重增加及低血糖发作[3]，是临床上较难解决的问题之一。利拉鲁肽作为一种胰高血糖素样肽-1(GLP-1)类似物，在降糖的同时有可减轻体重。本文主要研究二甲双胍联合利拉鲁肽治疗肥胖2型糖尿病的临床应用疗效及安全性，现报道如下。
1 对象与方法
1.1 研究对象
纳入2016年2月～2018年2月在我院门诊和病房就诊的2型糖尿病患者138例，随机分为对照组和试验组。对照组69例，男38例，女31例，平均年龄(64.36±6.17)岁，平均病程(8.93±0.84)年。试验组69例，男39例，女30例，平均年龄(65.53±6.20)岁，平均病程(9.42±0.91)年。所有患者均符合1999年WHO定义的2型糖尿病诊断标准。纳入标准;入选前所有患者均口服降糖药治疗;无胰岛素治疗史;体重指数>25 kg/m2;糖化血红蛋白(HbA1c)>8.5%[4]。排除标准：肝肾功能不全者;恶性肿瘤者;妊娠、哺乳期女性;急性感染或应激者;慢性甲状腺疾病者;精神疾病和功能障碍者;慢性胰腺炎患者;严重心脑血管疾病者[5]。两组患者基本资料比较，差异无统计学意义(P>0.05)。, 百拇医药(仇海燕 孔利萍 马丽珍)